Sanofi acquires OTC rights to Tamiflu

Sanofi has signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the US.

The agreement means Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketing, scientific engagement and distribution of Tamiflu OTC in the US.

Additionally, Sanofi will be responsible for leading the clinical program and funding all studies needed to support the OTC switch in the US in consultation with leading experts in the field.

Tamiflu is currently sold in the US by Roche Group member Genentech for prescription use. Roche will continue to market Tamiflu in the rest of the world.

Alan Main, Executive Vice President of Consumer Healthcare at Sanofi, said: “The US market is the largest OTC market in the world and a successful switch of Tamiflu to OTC would support our global cough and cold strategy by expanding into flu with a sustainable point of difference in the market.

“Tamiflu will offer a significant public health benefit once switched by providing increased access to a safe and efficacious treatment for the prevention and treatment of flu.

“People would be able to either reduce their chances of getting the flu or, at the first signals, appropriately treat as early as possible during the crucial first 48 hours without having to wait for a doctor’s appointment.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Teva & Alvotech join forces to commercialise biosimilars in US

Israel’s Teva Pharmaceutical and Icelandic biopharma Alvotech have entered into an exclusive strategic partnership for the commercialisation in the US of five biosimilar product...

Related news

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...